Protocol Ledger

NCT04746924 · Phase III · TERMINATED

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Interventional Phase III clinical trial protocol NCT04746924 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-24 Enrollment: 669 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04746924
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)669 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04746924
Protocol FieldVerified Registry Value
NCT IdentifierNCT04746924
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment669 participants (ACTUAL)
Registered Start Date2021-05-24
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04746924
Hospital Research SiteLocationSite Profile
Valkyrie Clinical TrialsLos Angeles, CAOpen Hospital Dossier ->
Baptist Health LexingtonLexington, KYOpen Hospital Dossier ->
Concord Repatriation General HospitalConcord, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI